Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis.
Bruce C TrapnellYoshikazu InoueFrancesco BonellaCliff MorganStéphane JouneauElisabeth BendstrupIlaria CampoSpyros A PapirisEtsuro YamaguchiErdogan CetinkayaMikhail M IlkovichMordechai R KramerMarcel VeltkampMichael KreuterTomohisa BabaCecilia GanslandtInge TarnowGrant WatererTaneli Jouhikainennull nullPublished in: The New England journal of medicine (2020)
In patients with aPAP, daily administration of inhaled molgramostim resulted in greater improvements in pulmonary gas transfer and functional health status than placebo, with similar rates of adverse events. (Funded by Savara Pharmaceuticals; IMPALA ClinicalTrials.gov number, NCT02702180.).